Bayer exploring sale of dermatology business: Bloomberg

September 8, 2016 1:31 PM EDT

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

(Reuters) - German chemicals and crop pesticides firm Bayer AG is exploring the sale of its dermatology business to push forward its deal with Monsanto Co (NYSE: MON), Bloomberg reported, citing sources.

Bayer is working with JPMorgan Chase & Co (NYSE: JPM) on the sale, which could fetch more than 1 billion euros ($1.12 billion), the report said. (

Bayer said on Monday it was willing to offer more than $65 billion, a 2 percent increase on its previous offer for the world's largest seeds company Monsanto.

The dermatology business could attract interest from existing makers of skincare products including Nestle SA's Galderma, Allergan Plc (NYSE: AGN) and Almirall SA (NYSE: ALM), as well as private equity firms, according to the Bloomberg report.

Bayer and J.P. Morgan were not immediately available for comment.

(Reporting by Aishwarya Venugopal in Bengaluru; Editing by Shounak Dasgupta)

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment